Medicine & Life Sciences
Cholangiocarcinoma
100%
Neoplasms
63%
Biliary Tract Neoplasms
44%
gemcitabine
29%
Pancreatic Neoplasms
29%
Survival
25%
Adenocarcinoma
24%
Receptor, Fibroblast Growth Factor, Type 2
24%
Therapeutics
23%
Mutation
22%
Hepatocellular Carcinoma
21%
Atlases
18%
Safety
17%
Genome
16%
Fibroblast Growth Factor Receptors
16%
Progression-Free Survival
15%
Oncolytic Viruses
14%
Maximum Tolerated Dose
14%
Cisplatin
14%
Immunotherapy
14%
Sorafenib
12%
Oncolytic Virotherapy
11%
Gallbladder Neoplasms
11%
130-nm albumin-bound paclitaxel
11%
Pharmacokinetics
11%
Circulating Tumor DNA
11%
Clinical Trials
11%
Precision Medicine
10%
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
10%
Isocitrate Dehydrogenase
10%
Genes
10%
ivosidenib
10%
Neoplasm Genes
10%
Drug Therapy
9%
TH 302
9%
HhAntag691
9%
Carcinoma
7%
Vesicular Stomatitis
7%
High-Throughput Nucleotide Sequencing
7%
Bevacizumab
7%
Liver
7%
Network Meta-Analysis
6%
Tumor Burden
6%
Biliary Tract
6%
Liver Transplantation
6%
Neoplasm Metastasis
6%
Viruses
6%
Oncogenes
6%
trifluridine tipiracil
6%
Liver Neoplasms
5%